Equities
Health CareHealth Care Equipment & Services
  • Price (USD)80.04
  • Today's Change-0.01 / -0.01%
  • Shares traded1.65m
  • 1 Year change-11.06%
  • Beta0.6377
Data delayed at least 15 minutes, as of Jan 15 2021 21:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

  • Revenue in USD (TTM)11.53bn
  • Net income in USD733.00m
  • Incorporated1931
  • Employees50.00k
  • Location
    Baxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
  • Phone+1 (847) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAX:NYQ since
announced
Transaction
value
Omnicell IncRumoured08 Dec 202008 Dec 2020Rumoured2.92%--
Data delayed at least 15 minutes, as of Jan 15 2021 21:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
West Pharmaceutical Services Inc.2.04bn311.70m22.07bn8.20k72.4212.8354.9110.834.124.1226.9423.260.85665.055.91248,451.2012.409.4814.8511.2034.8532.4914.4810.892.11--0.129521.647.135.3018.2513.722.438.27
ResMed Inc.3.03bn679.90m31.43bn7.77k46.5411.7337.5810.384.664.6620.7618.490.69013.036.20389,691.1015.5012.6217.8114.7558.2957.7122.4518.461.8015.530.282845.4413.4411.9951.4111.998.056.85
Zimmer Biomet Holdings Inc7.06bn-151.90m33.13bn19.90k--2.7938.024.69-0.7559-0.755934.0657.270.29230.875.67355,020.10-0.61981.45-0.70841.6070.1170.72-2.124.691.179.170.41153.740.621511.30405.109.4616.051.76
DexCom, Inc.1.82bn231.10m34.59bn3.90k149.1123.06118.4119.002.422.4219.0015.620.6053.826.02466,820.507.68-1.968.91-2.3166.3265.6512.69-2.246.005.920.5313--43.0841.61179.29--61.86--
Baxter International Inc11.53bn733.00m41.15bn50.00k57.164.8026.363.571.411.7622.4216.770.61673.676.05230,620.003.979.524.7411.9941.1242.296.4316.392.0613.440.429924.492.371.17-40.0012.04-18.18-16.14
Align Technology, Inc.2.29bn1.74bn43.59bn14.53k25.1514.3723.8419.0621.9921.9928.9438.470.67616.083.95157,412.8051.3818.6072.8226.4171.0474.1675.9919.471.20--0.000.0022.3925.8710.6324.8744.10--
Boston Scientific Corporation10.11bn-417.00m50.59bn36.00k--3.2571.565.00-0.29382.617.1310.870.3512.225.96280,805.60-1.393.27-1.594.1366.7070.79-3.957.201.423.330.37490.009.287.78-62.72--16.44--
Edwards Lifesciences Corp4.37bn796.90m54.75bn13.90k70.1813.0061.1512.531.251.256.926.760.68441.557.80314,295.0012.4815.1914.3018.1175.5074.3918.2421.992.61--0.12380.0016.7913.3642.245.2924.33--
Data as of Jan 15 2021. Currency figures normalised to Baxter International Inc's reporting currency: US Dollar USD

Institutional shareholders

37.09%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202037.08m7.26%
Wellington Management Co. LLPas of 30 Sep 202028.75m5.63%
BlackRock Fund Advisorsas of 30 Sep 202028.67m5.61%
SSgA Funds Management, Inc.as of 30 Sep 202022.22m4.35%
Morgan Stanley Investment Management Ltd.as of 30 Sep 202021.96m4.30%
Capital Research & Management Co. (International Investors)as of 30 Sep 202011.96m2.34%
Generation Investment Management LLPas of 30 Sep 202011.86m2.32%
Veritas Asset Management LLPas of 30 Sep 202010.95m2.14%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20208.17m1.60%
The Caisse de d�p�t et placement du Qu�becas of 30 Sep 20207.87m1.54%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.